Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies is viewed favorably because SGT-610 appears to address a large unmet need in Gorlin syndrome, where analysts cite roughly 11,000 to 12,000 diagnosed U.S. patients, no approved therapy, and potential peak sales above $600 million with rare-disease pricing near $170,000 per treatment course. The bullish case is reinforced by encouraging clinical and commercial signals, including a post-hoc analysis showing a 48% reduction in new BCC formation in a high-risk subgroup, physician feedback that over 50% of identified patients could be candidates, and a $269 million fully diluted market cap that looks modest versus the opportunity. Financially, the company’s March 2026 financing and approximately $52.8 million in end-1Q26 cash and marketable securities support operations through regulatory submission, while TWYNEO and EPSOLAY partnerships could add up to $4.5 million in milestones and about $10 million in annual royalties by 2031.

Sol-Gel Technologies is viewed negatively because its lead SGT-610 program still carries substantial binary risk after PellePharm’s prior Phase 3 missed statistical significance, and the current trial is being tested in a population selected from a retrospective signal that may not replicate prospectively. Even with estimated 11,000-12,000 U.S. patients and limited alternatives, the commercial case is weakened by high discontinuation and dropout risk, while the prior study showed 29% missing 12-month assessments and diluted efficacy signals in a low-baseline lesion setting. The company’s DCF implies about $414M for the commercial and late-stage portfolio, but a 40% approval probability for SGT-610 and the possibility of long-term dilution underscore fragile fundamentals.